[go: up one dir, main page]

TR200604485T1 - Bir immün tepkinin bastırılması veya proliferatif bir hastalığın tedavisi - Google Patents

Bir immün tepkinin bastırılması veya proliferatif bir hastalığın tedavisi

Info

Publication number
TR200604485T1
TR200604485T1 TR2006/04485T TR200604485T TR200604485T1 TR 200604485 T1 TR200604485 T1 TR 200604485T1 TR 2006/04485 T TR2006/04485 T TR 2006/04485T TR 200604485 T TR200604485 T TR 200604485T TR 200604485 T1 TR200604485 T1 TR 200604485T1
Authority
TR
Turkey
Prior art keywords
substituted
treatment
suppression
immune response
subject
Prior art date
Application number
TR2006/04485T
Other languages
English (en)
Inventor
Kristof Arnold
Moss Joel
Original Assignee
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services filed Critical The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services
Publication of TR200604485T1 publication Critical patent/TR200604485T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)

Abstract

Burada, bir denekte immün tepkinin bastırılması, denekte neoplazmanm tedavisi veya denekte fıbroproliferatif damar hastalığının tedavisi için, deneğe Formül (A)'daki yapıya sahip olan bir 2-(4-piperazinil) ikameli 4H-l-benzopiran-4-one bileşiği veya onun farmasötik açıdan kabul edilebilir bir tuzunun etkin bir miktarının verilmesini içeren usuller anlatılmakta olup, burada Rı ve R2'den her birinin varlığı isteğe bağlıdır ve Rı ve R2, her biri bağımsız olarak alkil, ikameli alkil, heteroalkil, sikloalkil, ikameli sikloalkil, heterosikloalkil, ikameli heterosikloalkil, aril, ikameli aril, heteroaril, ikameli heteroaril, alkoksi, halojen, hidroksi veya amino arasından seçilir.
TR2006/04485T 2003-12-09 2004-12-09 Bir immün tepkinin bastırılması veya proliferatif bir hastalığın tedavisi TR200604485T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52834003P 2003-12-09 2003-12-09

Publications (1)

Publication Number Publication Date
TR200604485T1 true TR200604485T1 (tr) 2007-01-22

Family

ID=34676839

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2006/04485T TR200604485T1 (tr) 2003-12-09 2004-12-09 Bir immün tepkinin bastırılması veya proliferatif bir hastalığın tedavisi
TR2008/08208T TR200808208T1 (tr) 2003-12-09 2004-12-09 Bir immün tepkinin bastırılması veya proliferatif bir hastalığın tedavisi

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2008/08208T TR200808208T1 (tr) 2003-12-09 2004-12-09 Bir immün tepkinin bastırılması veya proliferatif bir hastalığın tedavisi

Country Status (16)

Country Link
US (2) US8044057B2 (tr)
EP (1) EP1694331B8 (tr)
JP (1) JP2007513962A (tr)
KR (1) KR20060123463A (tr)
CN (1) CN1889958A (tr)
AT (1) ATE447957T1 (tr)
AU (1) AU2004296868B2 (tr)
BR (1) BRPI0417498A (tr)
CA (1) CA2546920A1 (tr)
DE (1) DE602004024115D1 (tr)
IL (1) IL176214A0 (tr)
MX (1) MXPA06006651A (tr)
RU (1) RU2006124421A (tr)
TR (2) TR200604485T1 (tr)
WO (1) WO2005056014A1 (tr)
ZA (1) ZA200604724B (tr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
CA2651367A1 (en) * 2005-05-11 2006-11-16 Genetic Technologies Limited Methods of enriching fetal cells
US8101625B2 (en) * 2005-10-21 2012-01-24 Exelixis, Inc. Pyrimidinones as Casein Kinase II (CK2) modulators
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
US20070212388A1 (en) * 2006-03-08 2007-09-13 Sahajanand Medical Technologies Pvt. Ltd. Compositions comprising porous articles and uses in implantable medical devices
EP2170338A2 (en) * 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs modulates energy regulation and brain function
JP5642714B2 (ja) 2009-02-11 2014-12-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規なアミノアザヘテロ環式カルボキサミド
BR112012002336A2 (pt) 2009-08-07 2016-05-31 Merck Patent Gmbh compostos aza-heterocíclicos
CN101849934B (zh) * 2010-05-25 2011-11-09 苏州大学 一种磷脂酰肌醇-3-激酶抑制剂及其应用
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
WO2012016001A1 (en) 2010-07-29 2012-02-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
SI2643313T1 (sl) 2010-11-24 2016-11-30 Merck Patent Gmbh Kinazolin-karboksamidni azetidini
UY34013A (es) 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
AP4075A (en) * 2011-05-04 2017-03-23 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
WO2013040059A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Novel imidazole amines as modulators of kinase activity
WO2013040044A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
CN104169258B (zh) 2011-12-22 2017-03-01 默克专利有限公司 用作激酶活性调节剂的新颖的杂环羧酰胺
EP2822558B1 (en) 2012-03-06 2020-02-19 The Board of Trustees of the University of Illionis Procaspase 3 activation by combination therapy
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
WO2014078634A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel imidazol-piperidinyl derivatives as modulators of kinase activity
WO2014085528A1 (en) 2012-11-29 2014-06-05 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
ES2754034T3 (es) 2013-03-04 2020-04-15 Astrazeneca Ab Combinación para el tratamiento de cáncer
WO2014143612A1 (en) 2013-03-11 2014-09-18 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
WO2015149909A1 (en) 2014-04-03 2015-10-08 Merck Patent Gmbh Combinations of cancer therapeutics
CN108929329B (zh) * 2017-05-24 2020-12-11 中国医学科学院药物研究所 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物
CN107602520B (zh) * 2017-10-16 2019-06-14 厦门大学 一种含哌嗪环的类异黄酮化合物及其制备方法和应用
CN107641109B (zh) * 2017-10-16 2019-05-24 厦门大学 一种类黄酮化合物及其制备方法和应用
EP3710433A4 (en) 2017-11-17 2022-01-12 The Board of Trustees of the University of Illinois CANCER THERAPY BY REMOVAL OF DOUBLE MEK SIGNALING
CN113329749B (zh) 2018-10-05 2025-02-11 伊利诺伊大学董事会 用于治疗葡萄膜黑色素瘤的联合疗法
JOP20210154B1 (ar) 2018-12-20 2023-09-17 Amgen Inc مثبطات kif18a
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
KR20230110296A (ko) 2020-11-16 2023-07-21 메르크 파텐트 게엠베하 암 치료를 위한 키나제 억제제 조합
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (tr) 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
FI912995A7 (fi) * 1988-12-21 1991-06-19 Upjohn Co Antiateroskleroottisia ja antitromboottisia 1-bentsopyran-4-oneja ja 2 -amino-1,3-bentsoksatsin-4-oneja
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US20030050692A1 (en) 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents

Also Published As

Publication number Publication date
MXPA06006651A (es) 2006-08-11
CA2546920A1 (en) 2005-06-23
DE602004024115D1 (de) 2009-12-24
US8044057B2 (en) 2011-10-25
WO2005056014A1 (en) 2005-06-23
AU2004296868B2 (en) 2010-11-25
WO2005056014A8 (en) 2006-08-31
EP1694331A1 (en) 2006-08-30
TR200808208T1 (tr) 2008-12-22
US20070173514A1 (en) 2007-07-26
EP1694331B1 (en) 2009-11-11
RU2006124421A (ru) 2008-01-20
KR20060123463A (ko) 2006-12-01
US20120039903A1 (en) 2012-02-16
ATE447957T1 (de) 2009-11-15
EP1694331B8 (en) 2010-02-24
BRPI0417498A (pt) 2007-05-29
ZA200604724B (en) 2010-01-27
IL176214A0 (en) 2006-10-05
AU2004296868A1 (en) 2005-06-23
CN1889958A (zh) 2007-01-03
JP2007513962A (ja) 2007-05-31

Similar Documents

Publication Publication Date Title
TR200604485T1 (tr) Bir immün tepkinin bastırılması veya proliferatif bir hastalığın tedavisi
NO20061788L (no) HIV-replikasjonshemmede purinderivater
WO2003057225A3 (en) Phosphate transport inhibitors
BRPI0411365A (pt) derivados de aminopiridina
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
EA201270275A1 (ru) Кристаллическое соединение пиридазина
EA200501820A1 (ru) Терапевтические средства для лечения боли
DK1539700T3 (da) 8-hydroxyquinolin-derivater
DE60010076D1 (de) Chinolinderivate als antibakterielle mittel
EA200300982A1 (ru) Гетероциклические производные для лечения рака и других пролиферативных заболеваний
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
EP2266969A3 (en) 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors
CY1106746T1 (el) Χρηση του irbesartan για την προληψη ή τη θεραπεια της πνευμονικης υπερτασης
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
NO20044548L (no) Fremgangsmate for fremstilling av 6-alkaliden-penemderivater
DK1412332T3 (da) Quinolinderivater og anvendelse deraf som antitumormidler
BR0213176A (pt) Derivados microbiocidas de n-fenil-n-[4-(4-piridil)-2-pirimidin-2-il]amina
NO20030500D0 (no) Dihydroporfyrinderivater og deres anvendelse
DE60211866D1 (de) Thiophen substituierte amin derivate als glyt-1 inhibitoren
EA200700098A1 (ru) Производные 4-арилморфолин-3-она, их получение и их применение в терапии
ATE398452T1 (de) 6-aryl-7-halo-imidazoä1,2-aüpyrimidine als mittel gegen krebs